Form 4: Marimed Inc. CEO Jon R. Levine Reports Stock Transactions

Jon R. Levine, President and CEO of Marimed Inc., reports the vesting of Restricted Stock Units (RSUs) and subsequent tax withholding, as well as adjustments to his direct and indirect beneficial ownership of common stock.

Summary

• On May 7, 2025, Jon R. Levine, the President and CEO of Marimed Inc., reported transactions involving the company's stock.
• 75,000 Restricted Stock Units (RSUs) vested, converting into 75,000 shares of common stock at a price of $0 per share.
• 25,988 shares of common stock were withheld by Marimed Inc. to cover tax obligations related to the vesting of the RSUs, priced at $0.101 per share.
• Levine's direct ownership of common stock decreased from 20,734,529 to 20,708,541 shares after the transactions.
• Levine also indirectly owns 6,684,640 shares through the Jon Levine Family Trust.
• Additionally, 269,578 RSUs were acquired on May 9, 2025.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It simply reports transactions and doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• The vesting schedules and tax withholding practices are typical components of executive compensation packages in similar companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the CEO's stock ownership.
• Employees may be indirectly affected by the executive's stock-based compensation.

Key Dates

Keywords

Form 4, MRMD, Marimed Inc., Jon R. Levine, Restricted Stock Units, RSU, Beneficial Ownership, Stock Transactions, Insider Trading